• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimism and caution for an inactivated COVID-19 vaccine.

作者信息

Rostad Christina A, Anderson Evan J

机构信息

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, USA.

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

出版信息

Lancet Infect Dis. 2021 May;21(5):581-582. doi: 10.1016/S1473-3099(20)30988-9. Epub 2021 Jan 21.

DOI:10.1016/S1473-3099(20)30988-9
PMID:33485467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7825871/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d029/7825871/8cc6928f79b7/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d029/7825871/8cc6928f79b7/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d029/7825871/8cc6928f79b7/fx1_lrg.jpg

相似文献

1
Optimism and caution for an inactivated COVID-19 vaccine.对一款新冠病毒灭活疫苗的乐观态度与谨慎考量。
Lancet Infect Dis. 2021 May;21(5):581-582. doi: 10.1016/S1473-3099(20)30988-9. Epub 2021 Jan 21.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.一项在 18-59 岁健康成年人中评估 SARS-CoV-2 灭活疫苗的有效性、安全性和免疫原性的 III 期、观察者盲法、随机、安慰剂对照研究：印度尼西亚的中期分析。
Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24.
4
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.一种灭活全病毒 SARS-CoV-2 疫苗（克尔来福）的有效性和安全性：在土耳其进行的一项双盲、随机、安慰剂对照、3 期临床试验的中期结果。
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
5
The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.一项在中国 18-59 岁成年人中进行的灭活 SARS-CoV-2 疫苗的安全性和免疫原性的 I 期随机、双盲、对照试验。
Vaccine. 2021 May 12;39(20):2746-2754. doi: 10.1016/j.vaccine.2021.04.006. Epub 2021 Apr 9.
6
Inactivated COVID-19 vaccines to make a global impact.灭活新冠疫苗将产生全球影响。
Lancet Infect Dis. 2021 Jun;21(6):746-748. doi: 10.1016/S1473-3099(21)00020-7. Epub 2021 Feb 3.
7
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.在中国，一种灭活的 SARS-CoV-2 疫苗（国药 BBIBP-CorV）与四价裂解流感疫苗和 23 价肺炎球菌多糖疫苗联合接种的免疫原性和安全性：一项多中心、非劣效性、开放性、随机、对照、四期临床试验。
Vaccine. 2022 Aug 26;40(36):5322-5332. doi: 10.1016/j.vaccine.2022.07.033. Epub 2022 Jul 29.
8
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
9
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
10
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.

引用本文的文献

1
Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.在中国广东省疫情期间，灭活 COVID-19 疫苗对 B.1.617.2（德尔塔）变异株引起的疾病的有效性：一项队列研究。
Ann Intern Med. 2022 Apr;175(4):533-540. doi: 10.7326/M21-3509. Epub 2022 Feb 1.
2
Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2.SARS-CoV-2 衍生合成长肽的选择和 T 细胞抗原性。
J Gen Virol. 2022 Jan;103(1). doi: 10.1099/jgv.0.001698.
3
Heterologous prime-boost strategies for COVID-19 vaccines.

本文引用的文献

1
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.BBV152（一种全病毒灭活的新型冠状病毒疫苗候选物）在叙利亚仓鼠模型中的免疫原性和保护效力
iScience. 2021 Feb 19;24(2):102054. doi: 10.1016/j.isci.2021.102054. Epub 2021 Jan 9.
2
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗（BBV152）的安全性和免疫原性：一项双盲、随机、1 期临床试验。
Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
用于 COVID-19 疫苗的异源初免-加强策略。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taab191.
4
Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study.西太平洋和东南亚六个国家及地区新冠病毒灭活疫苗的经济学评估：一项建模研究
Infect Dis Model. 2022 Mar;7(1):109-121. doi: 10.1016/j.idm.2021.12.002. Epub 2021 Dec 10.
5
Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.灭活严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗（BBV152）诱导的针对有症状冠状病毒病（COVID-19）的保护作用。
Lancet. 2021 Dec 11;398(10317):2134-2135. doi: 10.1016/S0140-6736(21)02014-6. Epub 2021 Nov 11.
6
Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.对 COVID-19 进行免疫消毒：开发辅助性 T 细胞 I 和 II 激活疫苗是当务之急。
Biomed Pharmacother. 2021 Dec;144:112282. doi: 10.1016/j.biopha.2021.112282. Epub 2021 Oct 2.
7
Understanding the SARS-CoV-2 virus to mitigate current and future pandemic(s).了解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）以减轻当前及未来的大流行。
Virusdisease. 2021 Sep;32(3):390-399. doi: 10.1007/s13337-021-00696-1. Epub 2021 Jun 5.
8
Three-Dimensional Cell Cultures as a Research Platform in Lung Diseases and COVID-19.三维细胞培养作为肺部疾病和 COVID-19 研究平台。
Tissue Eng Regen Med. 2021 Oct;18(5):735-745. doi: 10.1007/s13770-021-00348-x. Epub 2021 Jun 3.
mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
7
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.